The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis
Abstract
Background WHO and Health Action International (HAI) have developed a standardised method for surveying medicine prices, availability, affordability, and price components in low-income and middle-income countries. Here, we present a secondary analysis of medicine availability in 45 national and subnational surveys done using the WHO/HAI methodology.Methods Data from 45 WHO/HAI surveys in 36 countries were adjusted for inflation or deflation and purchasing power parity. International reference prices from open international procurements for generic products were used as comparators. Results are presented for 15 medicines included in at least 80% of surveys and four individual medicines.Findings Average public sector availability of generic medicines ranged from 29.4% to 54.4% across WHO regions. Median government procurement prices for 15 generic medicines were 1.11 times corresponding international reference prices, although purchasing efficiency ranged from 0.09 to 5.37 times international reference prices. Low procurement prices did not always translate into low patient prices. Private sector patients paid 9-25 times international reference prices for lowest-priced generic products and over 20 times international reference prices for originator products across WHO regions. Treatments for acute and chronic illness were largely unaffordable in many countries. In the private sector, wholesale mark-ups ranged from 2% to 380%, whereas retail mark-ups ranged from 10% to 552%. In countries where value added tax was applied to medicines, the amount charged varied from 4% to 15%.Interpretation Overall, public and private sector prices for originator and generic medicines were substantially higher than would be expected if purchasing and distribution were efficient and mark-ups were reasonable. Policy options such as promoting generic medicines and alternative financing mechanisms are needed to increase availability, reduce prices, and improve affordability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Medicines consume up to 20-60% of health expenditure in developed and transitional countries, and in developing African nations, nearly 90% of the population buys medicines out of pocket, making medicines the second-largest item of family spending after food.32”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [32]
In the citing paper
“Medicines consume up to 20-60% of health expenditure in developed and transitional countries, and in developing African nations, nearly 90% of the population buys medicines out of pocket, making medicines the second-largest item of family spending after food.32”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [32]
In the citing paper
“Medicines consume up to 20-60% of health expenditure in developed and transitional countries, and in developing African nations, nearly 90% of the population buys medicines out of pocket, making medicines the second-largest item of family spending after food.32”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [32]
In the citing paper
“Every year, over 10 million people die needlessly because of the lack of availability to existence medicines, primarily in LMICs (Africa), and the cost of medicine is one of the most significant barriers to access.32”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [32]
In the citing paper
“Every year, over 10 million people die needlessly because of the lack of availability to existence medicines, primarily in LMICs (Africa), and the cost of medicine is one of the most significant barriers to access.32”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [32]
Citations
Cites
Mendis, S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.033647 · Cited by 487
Diabetes care in sub-Saharan Africa
Beran, D., & Yudkin, J. S. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69704-3 · Cited by 268
Babar, Z. U. D., Ibrahim, M. I. M., Singh, H., Bukahri, N. I., & Creese, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040082 · Cited by 200
International Price Comparisons for Pharmaceuticals
Danzon, P. M., & Kim, J. D. (1998) · PharmacoEconomics · doi:10.2165/00019053-199814001-00014 · Cited by 79
Bennett, S., Quick, J. D., & Velásquez, G. (1997) · Cited by 62
Vasan, A. (2006) · Bulletin of the World Health Organization · doi:10.2471/blt.05.025684 · Cited by 49
Price Differentiation and Transparency in the Global Pharmaceutical Marketplace
Ridley, D. B. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523070-00002 · Cited by 46
Methodological Aspects of International Drug Price Comparisons
Andersson, F. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304040-00003 · Cited by 27
Research works printed but not linked: 4
- Bala, 1998, Retail drug prices: the law of the jungle, Hainews, 100, 2
- Sagoo, 1999, HIV/AIDS: Improving access to essential drugs, Hainews, 110, 1
- Bala, 2000, Patents and prices, Hainews, 112, 1
- Madden, 2003, Comparing pilot survey results from different countries, Essential drugs monitor, 33, 19
Cited by
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
Van Boeckel, T. P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B. T., Levin, S. A., & Laxminarayan, R. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70780-7 · Cited by 2,280
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837
Bousquet, J., Mantzouranis, E., Cruz, A. A., Aït-Khaled, N., Baena-Cagnani, C. E., Bleecker, E. R., Brightling, C. E., Burney, P., Bush, A., Busse, W. W., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.07.019 · Cited by 741
Hypertension in developing countries
Ibrahim, M. M., & Damasceno, A. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60861-7 · Cited by 731
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Self-citation
Metadata
- Authors
- Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R.
- Affiliations
- World Health Organization (CH)
- Health Action International (NL)
- Corresponding author
- Cameron, A
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 373
- Issue
- 9659
- Pages
- 240-249
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2122047846
- Cited by
- 928
- References
- 8
- Citations by year
- 2026: 29 · 2025: 30 · 2024: 52 · 2023: 56 · 2022: 47 · 2021: 81 · 2020: 71 · 2019: 70 · 2018: 57 · 2017: 69 · 2016: 48 · 2015: 57 · 2014: 64 · 2013: 67 · 2012: 39
- FWCI
- 66.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- drug pricing, drug availability, drug affordability, generic drugs, international reference prices, purchasing power parity
- MeSH terms
- Antacids, Anti-Bacterial Agents, Data Collection, Developing Countries, Health Services Accessibility, Humans, Reference Standards, Cluster Analysis, Drugs, Generic, Private Sector, Public Sector, Anti-Asthmatic Agents, Drugs, Essential, Developed Countries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(08)61762-6
- The paper
- Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009). Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet. https://doi.org/10.1016/s0140-6736(08)61762-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.